Neurocrine Non Current Assets Total from 2010 to 2024

NBIX Stock  USD 135.41  1.25  0.91%   
Neurocrine Biosciences Non Current Assets Total yearly trend continues to be fairly stable with very little volatility. Non Current Assets Total are likely to outpace its year average in 2024. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
1996-03-31
Previous Quarter
1.6 B
Current Value
1.7 B
Quarterly Volatility
352.8 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many exotic indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
This module can also supplement Neurocrine Biosciences' financial leverage analysis and stock options assessment as well as various Neurocrine Biosciences Technical models . Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of Neurocrine Biosciences over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Neurocrine Biosciences' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

Neurocrine Non Current Assets Total Regression Statistics

Arithmetic Mean487,491,467
Geometric Mean122,536,997
Coefficient Of Variation123.29
Mean Deviation488,928,356
Median255,374,000
Standard Deviation601,007,326
Sample Variance361209.8T
Range1.7B
R-Value0.90
Mean Square Error75457.8T
R-Squared0.81
Slope120,652,768
Total Sum of Squares5056937.3T

Neurocrine Non Current Assets Total History

20241.7 B
20231.6 B
2022915.2 M
20211.1 B
2020718.5 M
2019475 M
2018255.4 M

About Neurocrine Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Neurocrine Biosciences income statement, its balance sheet, and the statement of cash flows. Neurocrine Biosciences investors use historical funamental indicators, such as Neurocrine Biosciences's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Neurocrine Biosciences investors may use each financial statement separately, they are all related. The changes in Neurocrine Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Neurocrine Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Neurocrine Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Assets Total1.6 B1.7 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Neurocrine Stock analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Stocks Directory
Find actively traded stocks across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.648
Earnings Share
3.68
Revenue Per Share
20.147
Quarterly Revenue Growth
0.226
Return On Assets
0.1008
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.